| Literature DB >> 31650006 |
Joseph B Dubé1, Tianzheng Lin1, Sarah Best1, Julia Truemner1, Patricia Sargeant2, Michael J Borrie1,2.
Abstract
INTRODUCTION: Innovative recruitment strategies are needed to better engage potential research participants at a preclinical stage of cognitive decline.Entities:
Keywords: Alzheimer's disease; Clinical trials; Community-based; Dementia; Mild cognitive impairment; Recruitment; Screening; Self-referral; Subjective cognitive decline
Year: 2019 PMID: 31650006 PMCID: PMC6804498 DOI: 10.1016/j.trci.2019.07.009
Source DB: PubMed Journal: Alzheimers Dement (N Y) ISSN: 2352-8737
Fig. 1Case-finding study methodology flow chart.
Fig. 2Screening, assessment, and study enrollment among case-finding study participants.
Case-finding study participant baseline demographics
| Demographic categories | Female | Male | |
|---|---|---|---|
| Social demographics | |||
| Number (%) | 134 (66) | 69 (34) | - |
| Age (years) | 68 ± 8 | 71 ± 8 | .011 |
| Secondary education (%) | 117/122 (96) | 65/68 (96) | ns |
| Reported to family doctor (%) | 69/127 (54) | 42/67 (63) | ns |
| Lives alone (%) | 36/111 (32) | 6/58 (10) | .001 |
| Risk factors | |||
| Regular alcohol consumption (%) | 85/124 (69) | 57/67 (85) | .015 |
| Smoking history (%) | 53/130 (41) | 41/69 (59) | .017 |
| Heart disease (%) | 13/112 (12) | 23/69 (33) | ns |
| Cerebrovascular accident (%) | 3/130 (2) | 1/69 (1) | ns |
| Type 2 diabetes (%) | 8/131 (6) | 10/69 (14) | ns |
| History of brain injury (%) | 24/130 (18) | 20/69 (29) | ns |
| Hypertension (%) | 58/132 (44) | 27/69 (32) | ns |
| Hyperlipidemia (%) | 50/131 (38) | 30/69 (43) | ns |
| Obesity (%) | 31/109 (28) | 10/61 (16) | ns |
| Depressive symptoms (%) | 42/130 (32) | 13/69 (19) | .047 |
Abbreviation: ns, not statistically significant.
Statistically significant P values.
Baseline clinical testing, enrollment, and dementia risk factors by clinical suspicion
| Characteristics | SCD (n = 95, 47%) | MCI (n = 90, 44%) | Dementia (n = 18, 9%) | ||
|---|---|---|---|---|---|
| Cognitive testing and enrollment | |||||
| MMSE (world) | 30 (1) | 28 (2) | 25 (4) | <.001 | <.001 |
| MMSE (serial 7) | 29 (2) | 27 (3) | 24 (4) | <.001 | <.001 |
| MoCA | 27 (3) | 23 (2) | 18 (3) | <.001 | <.001 |
| MoCA–MRIS | 23 (3) | 18 (5) | 14 (7) | <.001 | <.001 |
| GDS | 3 (4) | 3 (4) | 1 (3) | ns | ns |
| CSDD | 4 (6) | 5 (5) | 6 (5) | ns | ns |
| Study enrollment | 22/95 (23%) | 33/90 (37%) | 6/18 (33%) | ns | ns |
| Cognitive risk factors | |||||
| Age, years | 66 (8) | 70 (8) | 75 (7) | .002 | <.001 |
| Male | 25/95 (26%) | 35/90 (39%) | 9/18 (50%) | ns | ns |
| Secondary education | 88/90 (98%) | 84/87 (97%) | 11/15 (73%) | ns | .004 |
| Any alcohol consumption | 74/93 (80%) | 57/84 (68%) | 12/16 (75%) | ns | ns |
| Smoking history | 46/94 (49%) | 37/90 (41%) | 11/17 (65%) | ns | ns |
| Lives alone | 22/90 (24%) | 23/88 (26%) | 2/17 (12%) | ns | ns |
| Family history of dementia | 46/90 (51%) | 31/86 (36%) | 9/18 (50%) | .049 | ns |
| Heart disease | 12/93 (13%) | 22/89 (25%) | 3/17 (18%) | ns | ns |
| Cerebrovascular accident | 2/93 (2%) | 2/90 (2%) | 0/18 (0%) | ns | ns |
| Type 2 diabetes | 7/93 (8%) | 9/90 (10%) | 2/17 (12%) | ns | ns |
| History of brain injury | 19/93 (20%) | 23/90 (26%) | 2/17 (12%) | ns | ns |
| Hypertension | 36/93 (39%) | 40/90 (44%) | 9/18 (50%) | ns | ns |
| Hyperlipidemia | 30/93 (32%) | 41/89 (46%) | 9/18 (50%) | ns | ns |
| Obesity | 18/80 (23%) | 21/77 (27%) | 2/13 (15%) | ns | ns |
| Depressive symptoms | 27/93 (29%) | 25/89 (28%) | 3/17 (18%) | ns | ns |
Abbreviations: MMSE, Mini–Mental Status Examination; MoCA, Montreal Cognitive Assessment; MRIS, memory recall index score; GDS, Geriatric Depression Scale; CSDD, Cornell scale for depression in dementia; ns, not significant.
Clinical tests reported as median values (interquartile range).
Statistically significant P value.
Frequency of explanations for non-enrollment in cognitive research among case-finding study participants
| Non-enrollment explanations | n (%) |
|---|---|
| Lost interest in participation | 36 (25) |
| No follow-up | 31 (22) |
| Declined available studies | 29 (20) |
| Ineligible for available studies | 29 (20) |
| Screen fail | 10 (7) |
| Other | 7 (6) |
Case-finding study participants with longitudinal follow-up by clinical suspicion
| Characteristics | SCD | MCI | Dementia | ||
|---|---|---|---|---|---|
| Number | 62/95 (65%) | 37/90 (41%) | 5/18 (28%) | .001 | .004 |
| Age, years | 66 (12) | 68 (12) | 82 (2) | .047 | .003 |
| Period, years | 2 (4) | 3 (4) | 2 (2) | ns | ns |
| Number of visits | 3 (2) | 3 (3) | 3 (1) | ns | ns |
Abbreviation: ns, not significant.
Age, period, and number of visits reported as median (interquartile range).
Statistically significant P value (<0.05) comparing MCI or dementia to SCD.